- |||||||||| Ruoxinlin (toludesvenlafaxine extended release) / Luye Group
Review, Journal: Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder-A Narrative Review. (Pubmed Central) - Mar 30, 2023
In conclusion, this review highlights the favorable clinical results of toludesvenlafaxine in only two short-term trials that enrolled patients with major depressive disorder (MDD) (efficacy and tolerability were good for up to eight weeks), indicating the need for more good quality, larger-sample, and longer-term trials. Exploring new antidepressants, such as TRI, can be considered a priority for clinical research due to the high rates of TRD, but also due to the significant percentages of relapse in patients with MDD.
- |||||||||| Clinical, P2 data, P3 data, Review, Journal: Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry. (Pubmed Central) - Jul 10, 2022
Exploring new antidepressants, such as TRI, can be considered a priority for clinical research due to the high rates of TRD, but also due to the significant percentages of relapse in patients with MDD. These new compounds with novel mechanisms of action are expected to provide a greater variety of treatment options for depression if preliminary positive results are confirmed.
- |||||||||| ansofaxine ER (LY03005) / Luye Group
Clinical, P2 data, Journal: Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial. (Pubmed Central) - May 7, 2022
These new compounds with novel mechanisms of action are expected to provide a greater variety of treatment options for depression if preliminary positive results are confirmed. Active doses (40, 80, 120, and 160 mg per day) of ansofaxine in a controlled setting were safe, tolerated, and effective in improving depression symptoms in MDD patients.
- |||||||||| ansofaxine ER (LY03005) / Luye Group
Preclinical, Journal: Epigenetic Mechanism of 5-HT/NE/DA Triple Reuptake Inhibitor on Adult Depression Susceptibility in Early Stress Mice. (Pubmed Central) - Apr 5, 2022
Hypermethylation and downregulation of oxytocin receptor (Oxtr) in the hippocampal tissues along with increased protein expression of Dnmt1 and Dnmt3a in mice that experienced the "two-hit" stress compared to those that only experienced adulthood social defeat stress, and LPM570065 could reverse these changes. Combined, these results suggest that methylation specificity of the gene Oxtr in the hippocampus may play an important role in early life stress-induced susceptibility to depression and that the5-HT/NE/DA triple reuptake inhibitor LPM570065 may reduce depression susceptibility via the reversal of the methylation of the gene Oxtr.
- |||||||||| ansofaxine ER (LY03005) / Luye Group
Journal: Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor. (Pubmed Central) - Oct 2, 2021
Plasma ODV exposure was proportionally related to the doses after oral dosing. These results suggest that toludesvenlafaxine is a triple reuptake inhibitor with relatively fast-acting antidepressant-like activity and good therapeutic profile including improvement of anhedonia and sexual function.
- |||||||||| Ruoxinlin (toludesvenlafaxine extended release) / Luye Group
Trial completion: A Relative Bioavailability Food Effect Study of LY03005 (clinicaltrials.gov) - Aug 6, 2019
P1, N=34, Completed,
These results suggest that toludesvenlafaxine is a triple reuptake inhibitor with relatively fast-acting antidepressant-like activity and good therapeutic profile including improvement of anhedonia and sexual function. Recruiting --> Completed
- |||||||||| Valdoxan (agomelatine) / Servier, Novartis, Edronax (reboxetine) / Pfizer, Latuda (lurasidone oral) / Sumitomo Dainippon
Clinical, Review, Journal: The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. (Pubmed Central) - Jun 21, 2019
...The emerging antidepressants are: selective monoamine oxidase inhibitors (MAOIs) such as bifemelane, pirlindole, toloxatone, selegiline, rasagiline and safinamide; serotonin-norepinephrine reuptake inhibitors (SNRIs) such as ansofaxine, nefopam and levomilnacipran; norepinephrine reuptake inhibitors (NRIs) such as Reboxetine, viloxazine, teniloxazine (also known as sulfoxazine or sufoxazine), and atomoxetine; Vilazodone (a serotonin 5-HT autoreceptor partial agonist with serotonin reuptake inhibition [SPARI]); Vortioxetine (a serotonin receptors antagonist with serotonin reuptake inhibition [SARI]); atypical antipsychotics such as olanzapine, quetiapine, risperidone, lurasidone, aripiprazole and brexpiprazole; N-methyl-d-aspartate (NMDA)-glutamatergic neurotransmission system blockers such as ketamine, CP-101,606 (traxoprodil), GLYX-13 (rapastinel), NRX-1074 (Apimostinel) and Riluzole...receptors antagonist [MASSA]) remains a paradoxical agent that doesn't fit into any of the currently available classes of antidepressant agents and its pharmacological properties also deemed it unfit and inappropriate to be classified into another separate novel class of antidepressants contrary to the reports published in previous reference literatures. Lastly, this review remarkably advocates for the incorporation of the atypical antipsychotics and NMDA-glutamatergic ionoceptor blockers as new member classes of the antidepressant agents because of their clinically significant roles in the management of depression disorders.
- |||||||||| Ruoxinlin (toludesvenlafaxine extended release) / Luye Group
New P1 trial: A Study of LY03005 vs Pristiq (clinicaltrials.gov) - Nov 7, 2018
P1, N=56, Completed,
- |||||||||| Ruoxinlin (toludesvenlafaxine extended release) / Luye Group
Trial completion: Relative Bioavailability (RBA) Study of LY03005 vs Pristiq (clinicaltrials.gov) - Jan 4, 2018
P1, N=20, Completed,
Lastly, this review remarkably advocates for the incorporation of the atypical antipsychotics and NMDA-glutamatergic ionoceptor blockers as new member classes of the antidepressant agents because of their clinically significant roles in the management of depression disorders. Recruiting --> Completed
- |||||||||| Ruoxinlin (toludesvenlafaxine extended release) / Luye Group
Trial completion, Trial primary completion date: Pilot BA Study of New LY03005 vs Pristiq (clinicaltrials.gov) - Mar 19, 2017
P1, N=20, Completed,
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Dec 2016
|
